Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 6/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
| ▸ | HSPA9 | P38646 | 3/20 | 0.58 |
| ▸ | HSPA5 | P11021 | 6/20 | 0.57 |
| ▸ | FFAR2 | O15552 | 3/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | HSPA2 | P54652 | 1/20 | 0.56 |
| ▸ | XBP1 | P17861 | 1/20 | 0.52 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | HSPA8 | P11142 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7876872 | 1.00 | LMNA (0.59) | LMNATSHRHSPA9HSPA5FFAR2 | |
| Bromide SCHEMBL11310643 | 0.97 | LMNA (0.57) | LMNATSHRHSPA9HSPA5FFAR2 | |
| SCHEMBL7868173 | 0.90 | LMNA (0.56) | LMNATSHRHSPA9HSPA5FFAR2 | |
| Bromide SCHEMBL11317007 | 0.85 | LMNA (0.57) | LMNATSHRHSPA9HSPA5FFAR2 | |
| SCHEMBL7415644 | 0.85 | HSPA5 (0.60) | LMNATSHRHSPA9HSPA5FFAR2 | |
| SCHEMBL6056801 | 0.85 | LMNA (0.51) | LMNATSHRHSPA9HSPA5FFAR2 | |
| SCHEMBL6056845 | 0.85 | HSPA5 (0.60) | LMNATSHRHSPA9HSPA5FFAR2 | |
| Hydrochloric Acid SCHEMBL7381658 | 0.84 | LMNA (0.50) | LMNATSHRHSPA9HSPA5FFAR2 | |
| Hydrochloric Acid SCHEMBL7417556 | 0.84 | HSPA5 (0.59) | LMNATSHRHSPA9HSPA5FFAR2 | |
| SCHEMBL1107000 | 0.83 | ADORA2A (0.68) | LMNATSHRHSPA9HSPA5FFAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230091297-A1 | INHIBITORS OF HSP70 PROTEINS | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA | 2023-03-23 | — | — | US | disclosed |
| WO-2021183942-A1 | INHIBITORS OF HSP70 PROTEINS | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2021-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230091297-A1 | INHIBITORS OF HSP70 PROTEINS | HSPA2, HSP90AB2P, HSP90AB1 | LMNA 3688/4885TSHR 4598/4885HSPA9 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.